DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DiaMedica Therapeutics Inc. (DMAC)
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm
Check Earnings Report
Company Research
Source: Business Wire
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on September 18, 2025, it granted stock options to purchase an aggregate of 490,000 shares of DiaMedica’s common stock to five newly hired non-executive employees whose employment commenced in August and September 2025.The stock options were approved by the Compensation Committee of the Board of Directors under the DiaMedica Therapeutics, Inc. Amended and Restated 2021 Employment Inducement Incentive Plan. The options have an exercise price of $6.76 per share, which is equal to the closing price of the Company’s common stock on September 18, 2025, and vest and become exercisable, on a cumulative basis, with respect to 25% of such underlying shares on the one-year anniversary of the grant date and with respect to the remaining 75% of such
Show less
Read more
Impact Snapshot
Event Time:
DMAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DMAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DMAC alerts
High impacting DiaMedica Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DMAC
News
- DiaMedica Therapeutics (NASDAQ:DMAC) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.MarketBeat
- DiaMedica signals revised ReMEDy2 trial timeline and expansion cohort completion for DM199 amid cash runway into 2027 [Seeking Alpha]Seeking Alpha
- DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]Yahoo! Finance
- DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business HighlightsBusiness Wire
DMAC
Earnings
- 11/12/25 - Miss
DMAC
Sec Filings
- 11/25/25 - Form 4
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- DMAC's page on the SEC website